The ACCESS-TAVI trial demonstrated that a combined suture/plug-based vascular closure device strategy significantly reduces ...
JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, showcased 2-year follow up data from the ALIGN-AR Trial at TCT 2024. Concurrently, the ...
A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...
LONDON — Two years after the large multinational PROTECTED TAVR trial failed to associate a cerebral embolic protection (CEP) device with significant protection from stroke in patients undergoing ...
This is due to the increasing prevalence of CVD and metabolic disorders. The global structural heart devices market, valued ...
China remains a core market for Edwards Lifesciences, especially with the ongoing improvements in the country's business ...
For patients with symptomatic and severe tricuspid regurgitation (TR), tricuspid transcatheter edge-to-edge repair (T-TEER) ...
Edwards Lifesciences Corp., Orange County’s most valuable publicly traded medical device maker, reported third quarter sales ...
Optoelectronic devices and components are those electronic devices that operate on both light and electrical currents. This can include electrically driven light sources such as laser diodes and ...
Surmodics, Inc. recently announced early results from its PROWL registry study of a subset of 60 real-world patients with acute ...
The 2024 edition of Transcatheter Cardiovascular Therapeutics (TCT) once again highlighted significant innovations in ...